The Role of Progesterone Receptors in Breast Cancer

Zhuo Li; Hongrui Wei; Siyan Li; Pei Wu; Xiaoyun Mao

doi:10.2147/DDDT.S336643

The Role of Progesterone Receptors in Breast Cancer

Drug Des Devel Ther. 2022 Jan 26:16:305-314. doi: 10.2147/DDDT.S336643. eCollection 2022.

Authors

Zhuo Li¹, Hongrui Wei¹, Siyan Li¹, Pei Wu², Xiaoyun Mao¹

Affiliations

¹ Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang City, Liaoning Province, People's Republic of China.
² Department of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang City, Liaoning Province, People's Republic of China.

Abstract

The progesterone receptor (PR) modulates estrogen receptors α (ERα) action in breast cancer; it is an upregulated target gene of ER, and its expression is dependent on estrogen. PR is also a valuable prognostic biomarker in breast cancer, especially in hormone-positive breast cancer. High expression of PR is more frequently observed in tumors with a better baseline prognosis (ie, luminal A) than tumors with a poor baseline prognosis (ie, luminal B). In the following review, we present the role of PR in breast cancer, including the genomic characteristics and pathways in breast cancer, PR and endocrine therapy.

Keywords: breast cancer; endocrine therapy; progesterone receptor.

Publication types

Review

MeSH terms

Breast Neoplasms / drug therapy
Breast Neoplasms / genetics
Breast Neoplasms / metabolism*
Breast Neoplasms / pathology
Female
Genomics
Humans
Receptors, Progesterone / metabolism*

Substances

Receptors, Progesterone

Grants and funding

This work was supported by the National Natural Science Foundation of China (No. 81972791). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.